Indications And Dose
Helicobacter pylori eradication [in combination with other drugs (see Helicobacter pylori infection p. 89)] ▶BY MOUTH ▶Adult: 30 mg twice daily for 7 days for first- and second-line eradication therapy; 10 days for third-line eradication therapy Benign gastric ulcer ▶BY MOUTH ▶Adult: 30 mg once daily for 8 weeks, dose to be taken in the morning Duodenal ulcer ▶BY MOUTH ▶Adult: 30 mg once daily for 4 weeks, dose to be taken in the morning; maintenance 15 mg once daily NSAID-associated duodenal ulcer | NSAID-associated gastric ulcer ▶BY MOUTH ▶Adult: 30 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed Prophylaxis of NSAID-associated duodenal ulcer | Prophylaxis of NSAID-associated gastric ulcer ▶BY MOUTH ▶Adult: 15–30 mg once daily Zollinger–Ellison syndrome (and other hypersecretory conditions) ▶BY MOUTH ▶Adult: Initially 60 mg once daily, adjusted according to response, daily doses of 120 mg or more given in two divided doses Gastro-oesophageal reflux disease ▶BY MOUTH ▶Adult: 30 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed; maintenance 15–30 mg once daily, doses to be taken in the morning Severe oesophagitis ▶BY MOUTH ▶Adult: 30 mg once daily for 8 weeks, continue as maintenance treatment if appropriate Severe oesophagitis, refractory to initial treatment ▶BY MOUTH ▶Adult: 30 mg twice daily Functional dyspepsia ▶BY MOUTH ▶Adult: 15 mg once daily for 4 weeks Uninvestigated dyspepsia ▶BY MOUTH ▶Adult: 30 mg once daily for 4 weeks l UNLICENSED USE Lansoprazole doses in BNF may differ from those in product literature. Lansoprazole may be used as detailed below, although these situations are considered outside the scope of its licence: . g treatment of severe oesophagitis, refractory to initial treatment, h see Gastro-oesophageal reflux disease p. 88 for further information; . g treatment of functional and uninvestigated dyspepsia, h see Dyspepsia p. 72 for further information.
Source page 106